Antivirals for the treatment of mild and moderate COVID-19 in South Africa
While the majority of COVID‐19 cases in South Africa (SA) are mild, patients with severe COVID‐19 requiring hospitalisation present with significant morbidity and mortality and place a substantial burden on healthcare services. Given the low vaccine uptake in SA and other low‐ and middle‐income...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
South African Medical Association
2023-12-01
|
| Series: | South African Medical Journal |
| Subjects: | |
| Online Access: | https://samajournals.co.za/index.php/samj/article/view/1066 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | While the majority of COVID‐19 cases in South Africa (SA) are mild, patients with severe COVID‐19 requiring hospitalisation present with significant morbidity and mortality and place a substantial burden on healthcare services. Given the low vaccine uptake in SA and other low‐ and middle‐income countries in sub‐Saharan Africa, the high prevalence of comorbidities and limited healthcare system capacity, evidence‐based interventions that reduce the risk of severe disease and death should be considered for implementation. Several antiviral classes have been newly developed or repurposed to treat COVID‐19 early after infection to retard progression to severe disease and reduce the risk of death, particularly in the elderly and/or in patients with comorbidities. COVID‐19 antivirals such as remdesivir, nirmatrelvir/ ritonavir and molnupiravir are safe and cost‐effective and have received either full approval or emergency use authorisation from regulators. Using a proposed test‐and‐treat strategy, judicious use of antivirals could be impactful.
|
|---|---|
| ISSN: | 0256-9574 2078-5135 |